Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer
October 07 2019 - 6:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other
diseases of the eye today announced the appointment of Charlene E.
Davis, Esq., as Vice President and Chief Compliance Officer,
reporting to John LaRocca, Aerie’s General Counsel. Ms. Davis will
oversee the world wide compliance and data privacy functions for
the Company. She most recently held a related position at Sun
Pharmaceutical Industries, Inc.
In connection with her acceptance of the position as Vice
President and Chief Compliance Officer, Ms. Davis will receive
awards totaling 50,060 stock options that will vest over 4 years,
with 25% vesting on the first anniversary of the hire date and the
remainder vesting ratably on each of the subsequent 36 monthly
anniversaries of the hire date. This award was made outside of
Aerie’s stockholder-approved equity incentive plan and was approved
by the Company’s independent directors as an inducement material to
Ms. Davis entering into employment with the Company in reliance on
NASDAQ Listing Rule 5635(c)(4), which requires this public
announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
retinal diseases and other diseases of the eye. Aerie's first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available at
www.rhopressa.com. Aerie’s second product for the reduction of
elevated intraocular pressure in patients with open-angle glaucoma
or ocular hypertension, Rocklatan® (netarsudil and latanoprost
ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose
combination of Rhopressa® and the widely-prescribed PGA
(prostaglandin analog) latanoprost, has been approved by the FDA
and is now available in the United States. In clinical trials of
Rocklatan®, the most common adverse reactions were conjunctival
hyperemia, corneal verticillata, instillation site pain, and
conjunctival hemorrhage. More information about Rocklatan®,
including the product label, is available at www.rocklatan.com.
Aerie continues to focus on global expansion and the development of
additional product candidates and technologies in ophthalmology,
including for wet age-related macular degeneration and diabetic
macular edema. More information is available at
www.aeriepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: our expectations
regarding the ability of the Company to attract and retain
executive talent, the ability of such talent to adequately
discharge their responsibilities, the commercialization and
manufacturing of Rhopressa® and Rocklatan® or any future product
candidates, including the timing, cost or other aspects of the
commercial launch of Rhopressa® and Rocklatan® or any future
product candidates; our commercialization, marketing, manufacturing
and supply management capabilities and strategies; the success,
timing and cost of our ongoing and anticipated preclinical studies
and clinical trials for Rhopressa® and Rocklatan®, with respect to
regulatory approval outside of the United States or additional
indications, and any future product candidates, including
statements regarding the timing of initiation and completion of the
studies and trials. We discuss many of the risks associated with
our business in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). Forward-looking statements are not
guarantees of future performance and our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191007005004/en/
Media: Tad Heitmann 949-526-8747 theitmann@aeriepharma.com
Investors: Ami Bavishi 908-947-3949 abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024